Trevena: $15 Million Non-Dilutive Tranche and General Business Update

$15 million tranche from ex-US royalty-based financing, triggered by first commercial sale of OLINVYK by Jiangsu Nhwa, Trevena’s partner in China

New OLINVYK respiratory data from VOLITION ~200 patient real-world outcomes study, using continuous respiratory monitoring, expected 3Q 2023

Three OLINVYK abstracts accepted for presentation at upcoming American Society of Anesthesiologists Meeting in 4Q 2023

Company to participate in upcoming HC Wainwright conference (September 11-13)

Company to Hold Conference Call on Wednesday, September 6 at 8 a.m. Eastern Time to discuss TRV045 Proof-of-Concept Data

The Company will host a conference call and webcast with the investment community on September 6, 2023 at 8:00 a.m. Eastern Time featuring remarks by Carrie Bourdow, President and Chief Executive Officer, Mark Demitrack, M.D., Senior Vice President and Chief Medical Officer, and Barry Shin, Chief Financial Officer.

Title:	Trevena Business Update Conference Call & Webcast
Date:	Wednesday, September 6, 2023
Time:	8:00 a.m. Eastern Time
Conference Call Details:	Toll-Free:1- 877-704-4453 International:1- 201-389-0920 Conference ID: 13740836
The conference call will be webcast live from the Company’s website and will be available via the following links:
Webcast:	https://viavid.webcasts.com/starthere.jsp?ei=1630911&tp_key=ea5c342481 https://www.trevena.com/investors/events-presentations/ir-calendar

The webcast should be accessed 15 minutes prior to the conference call start time. A replay of the webcast will be available following the conclusion of the live broadcast and will be accessible on the Company’s website.

https://finance.yahoo.com/news/trevena-announces-receipt-15-million-110100514.html